NeOnc Technologies Holdings, Inc.

NeOnc Technologies Holdings, Inc. is a clinical-stage life sciences company dedicated to the development and commercialization of central nervous system (CNS) therapeutics, primarily for brain cancer. The company's core mission is to address the persistent challenges in overcoming the blood-brain barrier to deliver effective treatments. Headquartered in Calabasas, California, NeOnc Technologies Holdings, Inc. operates from 23975 Park Sorrento, Suite 205.

The company's proprietary NEO™ drug development platform has yielded a portfolio of novel drug candidates and delivery methods, protected by patents extending to at least 2038. Its lead product candidates include NEO100, a purified form of perillyl acid administered intranasally, which is currently in Phase II clinical trials for glioblastoma and other high-grade gliomas. Another key candidate, NEO212, is a bio-conjugated chemotherapy agent combining temozolomide with perillyl alcohol, undergoing Phase I/II clinical trials for primary and metastatic brain tumors, including glioblastoma and meningioma.

NeOnc Technologies Holdings, Inc. became publicly traded on the Nasdaq Global Market under the ticker symbol NTHI on March 26, 2025. Amir F. Heshmatpour serves as the Chief Executive Officer, Executive Chairman, and President, having been appointed CEO in November 2025. Recent notable developments include receiving FDA feedback on NEO212 manufacturing requirements in July 2026 and securing UAE IND approvals for both NEO100 and NEO212 in June 2026, signaling an expansion of its global development efforts. The company also reported its Q1 2026 financial results in May 2026.